Clinical Trials Logo

Clinical Trial Summary

Researchers are trying to determine if heart injury occurs in subjects who undergo direct current cardioversion.


Clinical Trial Description

External transthoracic direct current (DC) cardioversion is a commonly used method of terminating cardiac arrhythmias. Conventional wisdom indicates that external DC cardioversion causes myocardial injury. Previous research has shown that DC cardioversion resulted in myocardial injury as evidenced by increased levels of cardiac troponin, even though those changes were modest. Many of these studies evaluated monophasic defibrillators and older, less sensitive cardiac troponin assays. The current standard is now to use modern biphasic defibrillators and new high sensitivity cardiac troponin assays (hs-cTnT). It is conceivable that the newer defibrillators may not cause myocardial injury. It would be important to understand if myocardial injury occurs in this setting and its approximate magnitude as it would the interpretation of hs-cTnT values in patients and therefore influenced diagnoses. It may be if a threshold energy level can be identified that is would also influence the choice of energy used to deliver the shock in this situation. A previous preliminary study documented no evidence of myocardial injury after elective DC cardioversion with modern day defibrillators. We aim to validate and expand that study here at Mayo Clinic Rochester. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04151966
Study type Observational
Source Mayo Clinic
Contact
Status Completed
Phase
Start date July 22, 2019
Completion date December 1, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03591627 - Left Atrial Thrombus on Transesophageal Echocardiography
Recruiting NCT01910779 - Optimization of Initial Energy for Cardioversion of Atrial Fibrillation With Biphasic Shocks N/A
Recruiting NCT02742207 - Renal Function Post Cardioversion for Atrial Fibrillation
Active, not recruiting NCT01924065 - Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation Phase 3
Active, not recruiting NCT04468321 - Heart Watch Study: a Pragmatic Randomized Controlled Trial N/A